VivoSim Labs (VIVS)
Nasdaq Market Closed
VivoSim Labs, Inc., formerly known as Organovo Holdings, Inc., is a biotechnology company focused on human-relevant disease modeling, drug development support, and therapeutic research. Its common stock trades under the symbol VIVS. The company’s work is centered on using advanced biological models, including three-dimensional human tissues, to better predict how drug candidates may behave in patients.
VivoSim’s therapeutic focus includes FXR314, a program being developed for inflammatory bowel disease, including ulcerative colitis. FXR, or farnesoid X receptor, is involved in biological pathways linked to gastrointestinal and liver function, making it a target of interest in diseases where inflammation, metabolism, and tissue health overlap. The company’s rationale for FXR314 is supported by preclinical work and evidence generated in 3D human tissue systems.
Alongside its internal development efforts, VivoSim provides research and predictive screening services to pharmaceutical and biotechnology companies. These services include liver toxicology testing intended to identify safety issues earlier in the drug development process. The company also works on models that can help assess intestinal side-effect profiles, which is important for therapeutic candidates across multiple stages of discovery and development.
VivoSim’s distinctive feature is the combination of a services platform and a targeted drug-development pipeline. By applying human tissue-based systems to both external customer work and internal programs, the company aims to improve translational insight compared with traditional preclinical approaches. Investors generally assess VivoSim by considering the progress of FXR314, demand for its screening services, scientific validation, and the funding required to advance biotechnology programs.
Last updated
- Market Cap
- $2,836,629
- P/E
- —
- P/FCF
- —
- P/S
- 19.98
- Enterprise Value
- -$1,451,371
- Sector
- Materials
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 11555 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121
VivoSim Labs Fall 34% After Pricing Up To $4 Million Public Offering
VivoSim launches $4M offering with warrants and two-tranche structure
NIO's January Deliveries Jump 96% Y/Y: More Tech Investment Ahead?
NIO January Deliveries Nearly Double Year On Year
Top Midday Gainers
Wall Street Set to Open Lower Friday as Investors React to Trump's Choice of Warsh as Fed Chair
VivoSim Expands Asia-Pacific Access To NAMKind Toxicology Services; Stock Skyrockets
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
Did Record 2025 Deliveries and a Multi‑Brand EV Push Just Shift NIO's (NIO) Investment Narrative?
NIO, XPeng & Li Auto Report December & Fourth-Quarter Delivery Results
NIO Posts Record December and Q4 Deliveries as 2025 Volumes Surge
How Investors Are Reacting To NIO (NIO) Surging November Deliveries Across Its Multi‑Brand EV Lineup
Nio Stock Slumps After Surprise November Delivery Drop
NIO Just Posted a 76% Delivery Surge--Here's What Investors Might Be Missing
NIO Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
NIO Stock Pops as EV Maker Smashes Delivery Record With 92% Surge
NIO Q3 Deliveries Rise 41% Y/Y: Is ONVO L90 Fueling the Growth?
NIO Stock Soars Past 52-Week High After Record Deliveries
NIO's August Deliveries Rise Y/Y: What's Driving the Momentum?
NIO's Q2 Loss Wider Than Expected, Revenues Increase Y/Y
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $2,836,629
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- -$1,451,371
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 0.64
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 19.98
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 0.13
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- -10.22
- EPS
- -0.42
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -$10,624,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -27.63%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -17.63%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.44
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.44
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.73
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $98,618
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 0.98
Income Statement
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Revenue | 26K | 28K | 37K | 51K | 24K |
| Gross profit | 26K | 28K | 37K | 51K | 22K |
| Operating income | -2.75M | -2.64M | -2.92M | -3.15M | -3.47M |
| EBITDA | -2.7M | -2.58M | -2.85M | -3.09M | -3.4M |
| Net income | -2.69M | -2.55M | -2.84M | 6.85M | -3.45M |
| Basic EPS | -1.03 | -0.98 | -1.14 | 4.9 | -2.28 |
| Diluted EPS | -1.03 | -0.98 | -1.14 | 4.9 | -2.28 |
Balance Sheet
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Total assets | 6.96M | 9.69M | 11.98M | 14.65M | 3.84M |
| Total liabilities | 2.52M | 2.62M | 2.44M | 4.16M | 3.48M |
| Total equity | 4.44M | 7.07M | 9.54M | 10.49M | 364K |
| Cash & equivalents | 4.29M | 6.68M | 9.06M | 11.31M | 1.16M |
| Current assets | 6.04M | 7.59M | 9.68M | 12.13M | 2.1M |
| Current liabilities | 2.48M | 2.45M | 2.14M | 3.74M | 2.94M |
Cash Flow
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Operating cash flow | -2.27M | -2.38M | -3.94M | -2.04M | -1.8M |
| Investing cash flow | — | — | — | 9M | 4K |
| Financing cash flow | -118K | 0 | 1.68M | 3.19M | -216K |
| Change in cash | -2.39M | -2.38M | -2.26M | 10.15M | -2.01M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | NT 10-K — VivoSim Labs, INC. | View Filing | |
| edgar index | SCHEDULE 13G — VivoSim Labs, INC. | View Filing | |
| edgar index | 8-K — VivoSim Labs, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B4 — VivoSim Labs, INC. | View Filing | |
| edgar index | CORRESP — VivoSim Labs, INC. | View Filing | |
| edgar index | CORRESP — VivoSim Labs, INC. | View Filing | |
| edgar index | EFFECT — VivoSim Labs, INC. | View Filing | |
| edgar index | CORRESP — VivoSim Labs, INC. | View Filing | |
| edgar index | CORRESP — VivoSim Labs, INC. | View Filing | |
| edgar index | S-1 — VivoSim Labs, INC. | View Filing | |
| edgar index | CORRESP — VivoSim Labs, INC. | View Filing | |
| edgar index | CORRESP — VivoSim Labs, INC. | View Filing | |
| edgar index | UPLOAD — VivoSim Labs, INC. | View Filing | |
| edgar index | DRS — VivoSim Labs, INC. | View Filing | |
| edgar index | 10-Q — VivoSim Labs, INC. | View Filing | |
| edgar index | 4 — VivoSim Labs, INC. | View Filing | |
| edgar index | 4 — VivoSim Labs, INC. | View Filing | |
| edgar index | 4 — VivoSim Labs, INC. | View Filing | |
| edgar index | 4 — VivoSim Labs, INC. | View Filing | |
| edgar index | 4 — VivoSim Labs, INC. | View Filing | |
| form 4 | Form 4 — STERN ADAM K | View Filing | |
| form 4 | Form 4 — Gobel David | View Filing | |
| form 4 | Form 4 — Milhous Alison Tjosvold | View Filing | |
| form 4 | Form 4 — Murphy Keith | View Filing | |
| form 4 | Form 4 — Cohen Douglas Jay | View Filing | |
| form 4 | Form 4 — Cohen Douglas Jay | View Filing | |
| form 4 | Form 4 — Cohen Douglas Jay | View Filing | |
| edgar index | 8-K — VivoSim Labs, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — VivoSim Labs, INC. | View Filing | |
| edgar index | 4 — VivoSim Labs, INC. | View Filing | |
| form 4 | Form 4 — Sethi Amar Akhtar | View Filing | |
| edgar index | 4 — VivoSim Labs, INC. | View Filing | |
| form 4 | Form 4 — Gobel David | View Filing | |
| edgar index | 10-Q — VivoSim Labs, INC. | View Filing | |
| edgar index | ARS — VivoSim Labs, INC. | View Filing | |
| edgar index | DEF 14A — VivoSim Labs, INC. | View Filing | |
| edgar index | DEFA14A — VivoSim Labs, INC. | View Filing | |
| edgar index | RW — VivoSim Labs, INC. | View Filing | |
| edgar index | S-8 — VivoSim Labs, INC. | View Filing | |
| edgar index | 4 — VivoSim Labs, INC. | View Filing | |
| edgar index | 3 — VivoSim Labs, INC. | View Filing | |
| edgar index | 8-K — VivoSim Labs, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-Q — VivoSim Labs, INC. | View Filing | |
| form 4 | Form 4 — Lialin Tony Serge | View Filing | |
| edgar index | 10-K/A — VivoSim Labs, INC. | View Filing | |
| edgar index | 10-K — VivoSim Labs, INC. | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | SCHEDULE 13G/A — VivoSim Labs, INC. | View Filing | |
| edgar index | 8-K — VivoSim Labs, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — VivoSim Labs, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ORGANOVO HOLDINGS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B5 — ORGANOVO HOLDINGS, INC. | View Filing | |
| edgar index | 8-K — ORGANOVO HOLDINGS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ORGANOVO HOLDINGS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ORGANOVO HOLDINGS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ORGANOVO HOLDINGS, INC. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ORGANOVO HOLDINGS, INC. | View Filing | |
| edgar index | 8-K — ORGANOVO HOLDINGS, INC. | View Filing | |
| edgar index | 424B5 — ORGANOVO HOLDINGS, INC. | View Filing | |
| edgar index | 8-K — ORGANOVO HOLDINGS, INC. | View Filing | |
| edgar index | 10-Q — ORGANOVO HOLDINGS, INC. | View Filing | |
| edgar index | SCHEDULE 13G/A — ORGANOVO HOLDINGS, INC. | View Filing | |
| edgar index | NT 10-Q — ORGANOVO HOLDINGS, INC. | View Filing | |
| edgar index | 8-K — ORGANOVO HOLDINGS, INC. | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free